Table 3.
Baseline characteristics of patients
| Characteristics | Intratympanic Dex (n = 58) | Topical IGF-1 (n = 60) | P value |
|---|---|---|---|
| Age-yr, mean ± SD | 50.1 ± 13.0 | 48.6 ± 14.0 | 0.557 |
| Male sex-no. (%) | 26 (44.8) | 28 (46.7) | 0.855 |
| No. of days for study entry from onset, mean (95% CI) | 16.3 (15.1–17.5) | 15.8 (14.6–17.0) | 0.574 |
| Hearing improvement by pre-treatment-no. (%) | |||
| >10 dB, <30 dB | 13 (22.4) | 17 (28.3) | 0.528 |
| <10 dB | 45 (77.6) | 43 (71.7) | |
| Hearing-dB pure-tone average, mean (95% CI) | |||
| Affected ear | 84.8 (79.1–90.4) | 85.6 (80.0–91.2) | 0.835 |
| Unaffected ear | 15.8 (12.4–19.2) | 20.4 (15.0–25.7) | 0.160 |
| Other symptoms-no. (%) | |||
| Dizziness/Vertigo | 23 (39.7) | 31 (51.7) | 0.202 |
| Tinnitus | 49 (84.5) | 51 (85) | >0.999 |
| Aural fullness | 44 (75.9) | 32 (53.3) | 0.013* |
An asterisk indicates statistical significance with Fisher’s exact test. Dex: dexamethasone.